Bioventus is excited to announce the publication of new data affirming that OSTEOAMP is a clinically viable alternative to Infuse (rhBMP-2).54
Matthew J. McGirt, MD, of Carolina NeuroSurgery & Spine Associates, led a retrospective analysis of outcomes involving patients who had transforaminal and posterior lumbar interbody fusion with either OSTEOAMP (n=330 patients) or Infuse (n=330 patients).54
The authors conclude that OSTEOAMP “is a clinically viable option for rhBMP-2” for single- and multilevel lumbar fusion. Further, the study demonstrates that OSTEOAMP provides clinically effective arthrdesis and improvements in PROMs (patient reported outcome measures) comparable to Infuse with a similar safety profile. The authors reported there were no differences in patient-reported outcome measures (PROMs) between rhBMP-2 at one year.54
Order copies for your clients
Use this form to order digital/print copies of McGirt et al, or to learn more about OSTEOAMP.
"*" indicates required fields
*Dr. McGirt is a paid consultant of Bioventus.
†In vitro performance may not be predictive of performance in humans.
‡OSTEOAMP may be used in situations where an autograft is appropriate. It should be restricted to homologous use for the repair, replacement, or reconstruction of musculoskeletal defects.
About OSTEOAMP and OSTEOAMP Select
Available in six formats to meet your unique surgical needs, OSTEOAMP and OSTEOAMP Select are differentiated allograft bone graft substitutes uniquely processed with bone and bone marrow. This process is designed to retain essential endogenous growth factors that align with and support each phase of the body’s natural bone healing process and has been shown to retain up to 23 different growth factors that support new bone formation.†‡1
OSTEOAMP is a registered trademark of Bioventus LLC.
Infuse is a trademark of Medtronics.